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Dear Sir,
Adequate anticoagulation is a precondi-
tion for any effective hemodialysis therapy
to prevent clotting in the extracorporeal cir-
cuit. While systemic anticoagulation with
unfractionated heparin has been widely
used, it is associated with several disadvan-
tages, such as an increase in bleeding risk.
Hemodialysis of patients who are at high risk
for hemorrhages is complicated by a 10–30%
incidence of bleeding [1, 2]. Alternatives to
conventional heparin anticoagulation that
are designed to reduce bleeding complica-
tions include limited-dose heparinization,
low-molecular-weight heparins, neutraliza-
tion of heparin with protamine, prostacyclin
infusion or saline-flush dialysis. Although
the incidence of bleeding complications can
be reduced, each of these methods has its
own limitations [3, 4].
The use of regional citrate anticoagula-
tion for hemodialysis and continuous renal
replacement therapies in patients at high risk
for bleeding offers unique advantages over
other anticoagulation alternatives [3–6]. By
virtue of chelating ionized calcium, citrate is
a powerful anticoagulant. Free calcium ions
are required for activation of coagulation
(fig. 1) but are also reported to have concen-
tration-dependent effects on clot polymeri-
zation [7–9].
Citrate anticoagulation is usually moni-
tored by the determination of activated clot-
ting time (ACT). However, this method is
affected by factor deficiencies and other an-
ticoagulants. Measuring ionized calcium by
ion-selective calcium electrodes may be an
inexpensive alternative way for monitoring
citrate effects in regional citrate anticoagula-
tion.
The aim of this study was to assess the
dose-response relationship of citrate anticoa-
gulation on coagulation activation and clot
formation in whole blood. In addition, the
value of direct determination of ionized cal-
cium by ion-selective calcium electrodes for
monitoring of citrate anticoagulation was
evaluated.
Venous blood was taken from 6 healthy
volunteers after informed consent and blood
samples we immediately analyzed. Coagula-
tion studies were performed with tubes con-
taining anticoagulant citrate dextrose-A
(ACD-A) in different amounts (0–5.65
mmol citrate/l of whole blood). ACD-A is an
isotonic mixture of dextrose, citrate acid,
and trisodium citrate (38 mmol/l anhydrous
citric acid, 75 mmol/l trisodium citrate) as
commonly used by blood banks for blood
sampling and cell storage.
Whole blood ACT was analyzed with a
KC4-coagulometer (Sigma-Amelung, Lem-
go, Germany) using kaolin as surface activa-
tor (100 ng of kaolin added to 0.3 ml of
whole blood). This test serves as a model for
contact activation (intrinsic pathway) and
determines the time until an initial forma-
tion of fibrin fibers is detected. Further, we
performed thromboelastography (TEG) with
a RoTEG analyser (Nobis, Endingen, Ger-
many) [10]. With this test, fibrin formation
kinetics and clot firmness are continuously
assessed (fig. 2). Results are given as clot for-
mation time (CFT; time from onset of clot
formation until a clot firmness of 20 mm is
attained) and maximum clot firmness
(MCF). To reveal the effects of citrate on
fibrin formation and clot polymerization, we
performed clotting times and thrombelasto-
grams using either kaolin as contact activa-
tor or the snake venom ecarin, which directly
activates prothrombin independently from
ionized calcium and earlier stages of the
coagulation cascade (0.2 U of ecarin added
to 0.3 ml of whole blood) (fig. 3). [11]. Ion-
ized calcium and blood pH were determined
by ion-selective electrodes on a Synthesis
1720 analyzer (Instrumentation Laboratory,
Kirchheim, Germany).
Studies using contact activation with
kaolin revealed a dose-dependent inhibition
of coagulation with increasing citrate concen-
trations (table 1). The correlation between
concentrations of ionized calcium and clot-
ting times revealed almost no anticoagulant
effect when ionized calcium levels were 10.50
mmol/l, while clotting times showed a steep
increase when calcium levels were further
decreased (fig. 4). 5.65 mmol/l citrate in-
duced clotting times of infinity in all samples.
In contrast to these findings, in coagulation
studies activated by ecarin, hemostasis pa-
rameters were not influenced at all (table 1).
Activation of clotting with kaolin
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Fig. 1. The importance of ionized calcium in the activation of coagu-
lation: ionized calcium is required for the formation of both tenase
and prothrombinase complex, which lead to thrombin activation and
finally to clot formation. Citrate acts by complexing ionized calcium
and thus it inhibits the activation of coagulation.
Fig. 2. Assessment of whole blood coagulation. a Coagulometric
technique: The blood sample is placed into a rotating cup. The move-
ment of a steel ball is detected magnetically. As soon as fibrin fibers
are formed, the viscosity of the sample rises and the movement of the
steel ball is stopped. By this technique the time interval from start of
the test to the initial formation of the fibrin fibers is detected.
b Thrombelastography: the blood sample is placed into a stationary
cup. A cylindrical pin oscillates. The blood clot reduces the move-
ment dependent on its firmness. With this technique, blood dynam-
ics of clot formation and clot firmness are assessed.
Table 1. Clotting time, clot formation time and clot firmness of blood samples anticoagulated with increasing
amounts of citrate
Citrate
mmol/l
Ionized Ca2+
mmol/l
Blood
pH
KC4: clotting
time, s
TEG: clot
formation time, s
TEG: clot
firmness, mm
0.00 1.18B0.05 7.39B0.02 101B9 82B15 65B4
1.13 0.67B0.07 7.38B0.03 108B13 81B17 66B5
2.26 0.40B0.04 7.35B0.04 157B51 102B28 63B4
3.39 0.28B0.03 7.32B0.04 327B175 167B64 56B6
4.52 !0.25 7.29B0.04 681B267 423B245 42B13
5.65 !0.25 7.25B0.04 no clotting no clotting no clotting
Activation of clotting with ecarin
0.00 1.20B0.08 7.40B0.03 101B9 74B16 68B3
5.65 !0.25 7.24B0.05 104B8 79B12 67B6
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Fig. 3. To evaluate the effect of citrate anti-
coagulation on clot formation and polymeri-
zation, coagulation studies were performed
using either kaolin (contact activation) or the
snake venom ecarin (direct prothrombin ac-
tivation). Effects of citrate anticoagulation
were assessed by clot formation time (coagu-
lometric detection) or clot firmness (throm-
belastographic analysis).
Fig. 4. Correlation of clotting time (a) and clot firmness (b) with ionized calcium. Coagulation triggered by contact
activation (addition of kaolin to non-anticoagulated whole blood).
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In summary, citrate anticoagulation in-
hibits coagulation, in a dose-dependent
manner. In concentrations used for regional
citrate anticoagulation, citrate inhibits acti-
vation of coagulation but does not directly
influence fibrin formation and clot polymer-
ization. The clinically relevant effects of ci-
trate anticoagulation rely alone on the dis-
turbed formation of the calcium-dependent
coagulation factor complexes. The anticoag-
ulant effects of citrate can be monitored eith-
er by methods that quantify clot formation
(i.e. ACT) or by direct assessment of ionized
calcium levels. Measuring concentrations of
ionized calcium by ion-selective electrodes
can be used as an inexpensive and precise
method of monitoring regional citrate anti-
coagulation.
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